Paweł Gordon

Dr. Paweł Gordon

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2026 in Biology
Verified
Journal Article
Open access
PDF file
PGPaweł Gordon
Paweł Gordon
Łukasz SzeleszczukŁukasz Szeleszczuk
Łukasz Szeleszczuk
MLMalgorzata Lasota
Malgorzata Lasota
Dariusz Maciej PisklakDariusz Maciej Pisklak
Dariusz Maciej Pisklak
Marcin GackowskiMarcin Gackowski
Marcin Gackowski
Factor Xa (FXa) remains an important target in the development of anticoagulant and antithrombotic agents. In this study, twenty isosteviol-derived oxime ether analogs previously reported as FXa inhibitors were used to develop a predictive QSAR model. The compounds were geometry-optimized at the B3LYP/6-311++G(d,p) level, and Dragon molecular descriptors were calculated from the optimized structures. After descriptor filtering, Random Forest-based supervised preselection and correlation-based pruning were applied. Several models of increasing complexity were evaluated, including multiple linear regression, additive MARSplines, and constrained second-order MARSplines models. The final model employed four active basis functions involving R6p+, C-025, ATSC7e, and Mor31p and demonstrated excellent calibration and cross-validated predictive ability (R2 = 0.929 and Q2_LOO = 0.865). Based on this model, twenty new isosteviol-derived analogs were designed and their activities were predicted after DFT optimization and descriptor calculation. Eight representative compounds were subsequently subjected to molecular docking against human factor Xa (PDB ID: 2P16), molecular dynamics simulations, MM/GBSA binding free energy calculations, and preliminary SwissADME/pkCSM profiling. Docking protocol validation yielded a redocking RMSD of 0.953 Å. Although ISV-M20 was the highest-ranked compound according to the QSAR model, subsequent receptor-based analyses identified ISV-M19, ISV-M04, and ISV-M06 as the derivatives with the most favorable combination of structural stability, persistent protein–ligand interactions, and binding free energies. The ADMET/toxicity screen further refined this prioritization: ISV-M19, ISV-M04, and ISV-M06 showed the most favorable preliminary toxicity balance among the prioritized derivatives, whereas ISV-M20 displayed additional developability liabilities, including very high lipophilicity, poor predicted solubility, P-gp substrate status, and a predicted hERG II alert. Overall, the results demonstrate that integrating interpretable QSAR modeling with receptor-based simulations and early ADMET/toxicity filtering provides a more balanced strategy for the rational design and prioritization of novel isosteviol-derived FXa inhibitors than any single computational approach alone.

30 June 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PGPaweł Gordon
Paweł Gordon
MJMichał Janiak
Michał Janiak
Katarzyna Mądra-GackowskaKatarzyna Mądra-Gackowska
Katarzyna Mądra-Gackowska
LWLidia Wydeheft
Lidia Wydeheft
IHIga Hołyńska-Iwan
Iga Hołyńska-Iwan
Marcin GackowskiMarcin Gackowski
Marcin Gackowski
Factor Xa (FXa) remains a clinically validated and chemically tractable anticoagulant target despite the therapeutic role of direct oral FXa inhibitors. Contemporary FXa inhibitor literature, however, is heterogeneous in scaffold design, endpoint reporting, assay consistency, translational depth, and suitability for computer-aided drug design (CADD). This review evaluates published series of small-molecule FXa inhibitors through a framework that combines translational structure–activity relationships (SARs), assay-aware data quality, and QSAR-readiness. A structured narrative synthesis focused mainly on post-2014 studies reporting discrete small-molecule or semisynthetic FXa inhibitors. Eligible series were classified as fully synthetic or natural-product-derived/semisynthetic chemotypes, and extraction covered scaffold architecture, potency endpoints, assay context, selectivity, clotting or antithrombotic readouts, PK/ADME, structural clarity, translational context, and extraction confidence. QSAR-readiness was assessed using analog density, congenericity, endpoint quality, assay comparability, activity range, structural interpretability, and curation burden. Fully synthetic chemotypes, particularly anthranilamide-derived and related scaffolds, provided the most coherent and modellable FXa datasets, whereas natural-product-derived and semisynthetic series expanded structural diversity. Many exploratory series, however, were limited by small analog sets, heterogeneous endpoints, incomplete translational characterization, narrow activity ranges, or higher curation burden. The practical value of published FXa inhibitor series, therefore, depends not only on potency but also on whether chemical and biological information can be reconstructed with confidence for reproducible SAR interpretation, local QSAR modeling, AI/ML-enabled CADD reuse, and clinical benchmark-aware prioritization. The QSAR-readiness framework is a critical triage tool, not a substitute for formal validation, distinguishing datasets suitable for curated local modeling from those better suited to qualitative SAR, scaffold inspiration, or translational hypotheses.

Verified
Journal Article
Open access
PDF file
AWAnna Wołowiec
Anna Wołowiec
ŁWŁukasz Wołowiec
Łukasz Wołowiec
AJAlbert Jaśniak
Albert Jaśniak
GGGrzegorz Grześk
Grzegorz Grześk
JBJacek Budzyński
Jacek Budzyński
MKMariusz Kozakiewicz
Mariusz Kozakiewicz
Epigenetic mechanisms, including DNA methylation and hydroxymethylation, contribute to inflammation, cardiac remodelling and progression of heart failure. Ten–Eleven Translocation (TET) dioxygenases are key regulators of these processes, but the impact of statins on TET proteins in human heart failure is not well characterised. We investigated how statin therapy relates to TET1, TET2 and TET3 expression in circulating immune cells in heart failure with reduced ejection fraction (HFrEF). In this cross-sectional study, 106 patients with HFrEF were enrolled; 84 were receiving statins and 22 were not. Intracellular TET1/2/3 protein levels were measured by multiparameter flow cytometry in granulocytes, monocytes and lymphocytes, and clinical and laboratory characteristics were compared between groups. Statin-treated patients had lower NT-proBNP concentrations and lower neutrophil, lymphocyte and monocyte counts, and more often received guideline-directed medical therapy. Statin therapy was associated with a distinct TET expression profile, characterised by higher TET1 and TET3 indices in monocytes and lymphocytes and lower TET2 indices in granulocytes and monocytes. This pattern is compatible with a distinct immune-cell TET expression profile aligned with the anti-inflammatory and reparative profile attributed to statins, and the course of disease. These associations do not establish causality and require prospective validation. TET proteins may form part of an epigenetic signature associated with statin treatment in heart failure and warrant further study as potential biomarkers in larger, prospective cohorts.

Verified
Journal Article
Open access
PDF file
PGPaweł Gordon
Paweł Gordon
MJMichał Janiak
Michał Janiak
Marcin GackowskiMarcin Gackowski
Marcin Gackowski
Monika Zielińska-PisklakMonika Zielińska-Pisklak
Monika Zielińska-Pisklak
Łukasz SzeleszczukŁukasz Szeleszczuk
Łukasz Szeleszczuk
An integrated computational workflow was developed to prioritize piperazinylanthranilamide factor Xa (FXa) inhibitor candidates. Twenty literature compounds were geometry-optimized and described using alvaDesc to construct a constrained additive multivariate adaptive regression splines model. Internal validation and an assessment of the applicability domain guided the evaluation of 20 prospective analogs. Ten selected analogs and two same-series references were docked to FXa, with apixaban as the crystallographic comparator. Thirteen initial 100 ns molecular dynamics simulations were supplemented by two independent runs for each of PAX-M09, PAX-M15, and PAX-M18. Binding energetics were assessed using molecular mechanics/generalized Born surface area (MM/GBSA), alongside in silico developability profiling. The model achieved R2 = 0.904 and an internal leave-one-out Q2 of 0.846. PAX-M09 was the strongest strict in-domain prediction, whereas PAX-M15 was borderline. Apixaban redocking yielded a root-mean-square deviation (RMSD) of 0.953 Å. Although PAX-M17 and PAX-M19 ranked highest in docking, subsequent analyses prioritized PAX-M15, PAX-M09, and PAX-M18. PAX-M15 showed the most consistent positional behavior across replicates and consistently favorable run-specific MM/GBSA estimates (−68.76, −70.11, and −69.42 kcal/mol). PAX-M09 and PAX-M18 showed greater between-run heterogeneity. Solubility, metabolic, and toxicity liabilities remained important. The results support experimental investigation of the three candidates without changing their applicability-domain classifications or establishing superior experimental potency.